NeoThetis: Breast / Gynecological
NeoThetis Breast/Gynaecological panel can test for genetic alterations which are commonly found in gynaecological cancers such as breast, ovarian and others. Different risk factors, such as inheritance, increasing age, and environmental factors, can contribute to the development of gynaecological cancers. This panel identifies the genetic mutations in 48 genes in circulating tumour DNA, which can help in therapy selection and re-evaluation. There are numerous /-approved therapies for gynaecological cancers depending on the type of cancer.
Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. The approved immunotherapy drug pembrolizumab is available for treating patients with MSI-high status. Pembrolizumab has also been approved by the for endometrial cancer.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

